The Most Important Facts About Abbott Laboratories

By Harris Dyer • Friday, June 27 09:59 • Permanent Link

Large-cap Health Care company Abbott Laboratories has moved 0.1% so far today on a volume of 566,609, compared to its average of 6,784,693. In contrast, the S&P 500 index moved 0.0%.

Abbott Laboratories trades -5.15% away from its average analyst target price of $141.12 per share. The 26 analysts following the stock have set target prices ranging from $120.12 to $159.0, and on average have given Abbott Laboratories a rating of buy.

If you are considering an investment in ABT, you'll want to know the following:

Abbott Laboratories's current price is 95.5% above its Graham number of $68.46, which implies that at its current valuation it does not offer a margin of safety
Abbott Laboratories has moved 28.6% over the last year, and the S&P 500 logged a change of 12.5%
Based on its trailing earnings per share of 7.7, Abbott Laboratories has a trailing 12 month Price to Earnings (P/E) ratio of 17.4 while the S&P 500 average is 29.3
ABT has a forward P/E ratio of 25.9 based on its forward 12 month price to earnings (EPS) of $5.16 per share
Its Price to Book (P/B) ratio is 4.77 compared to its sector average of 3.19
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
Based in North Chicago, the company has 114,000 full time employees and a market cap of $232.88 Billion. Abbott Laboratories currently returns an annual dividend yield of 1.7%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.